Piper Sandler raised the firm’s price target on Alnylam (ALNY) to $449 from $304 on a big AMVUTTRA beat, while keeping an Overweight rating on the shares following quarterly results. The firm notes Q2 AMVUTTRA sales of $492M crushed Street consensus of $357M driven by rapid ATTR-cardiomyopathy uptake in the first quarter of U.S. launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $550 from $403 at UBS
- Alnylam price target raised to $415 from $390 at Canaccord
- Alnylam Pharma: Strong Financials and Strategic Advancements Drive Buy Rating
- Alnylam price target raised to $405 from $312 at Morgan Stanley
- Cautious Optimism: Alnylam Pharma’s Strong TTR Franchise Growth and Hold Rating